Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin ®) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging

Inclusion Criteria: * Women over 18 years * Free and informed consent signed * Histologically confirmed adenocarcinoma of the breast, metastatic or non-metastatic * LVEF\> 50% angioscintigraphy before the start of treatment with Herceptin ®, * Overexpression of HER2 in the invasive component of the primary tumor (3 + 2 + according to ICH or with confirmation of positivity by FISH or CISH) * Patient receiving treatment with Herceptin ®, * Inclusion in the control group: patients treated with Herceptin ® episode without LV dysfunction, * For the inclusion in the Group LV dysfunction: the appearance of a decrease in LVEF during treatment with Herceptin ®, angioscintigraphy identified. Exclusion Criteria: * Heart disease or serious medical conditions do not allow to administer Herceptin ® (documented history of heart failure, angina requiring treatment, severe dyspnoea at rest or oxygen dependency), * History of ischemic heart disease or myocarditis * Known allergy to trastuzumab, murine proteins or any of the excipients * Patients with an indication against the MRI (claustrophobia, ferromagnetic foreign body, pacemaker or implantable defibrillator, known allergy to gadolinium salts) * Renal impairment (creatinine clearance \<60 ml / min according to the MDRD formula) * Arrhythmia atrial fibrillation, * Contraindications to the administration of Dotarem ®, * Patient unable to give informed consent, * Adult Trust, * Pregnant or lactating * Patient unable to undergo a medical for geographical, social or psychological.